The issue: Neurodegenerative diseases affect over a billion people worldwide; the human and economic cost of diseases like Fronto Temporal Dementia, Motor Neurone Disease (ALS, MND), Alzheimer’s, Parkinson’s and MS is huge.
The company: Nevrargenics’ technology is based on 19 years of world leading research at Durham and Aberdeen Universities and represents a major step-change in RAR-M based drug development. Its lead drug candidate is unique in that in modelling it indicates a potential for neurorepair (reversing disease). Nevrargenics’ vast IP library represents a new era in RAR-M based drug development and offers huge promise for ground-breaking progress in disease treatment.
Funding plan: The company was incorporated in the UK and technology transferred in 2019. Since then, Nevrargenics has raised equity of £0.75m and is now seeking £5m to fund manufacturing and trials for its lead drug, and second-generation drug development. EIS investment tax relief is available.
Value opportunity: The UK Regulator MHRA has green-lighted Phase I/IIa trials meaning that human results will be available within a year, providing a potentially very significant value creation/ inflection point. The company is already on the radar screen of a range of Big Pharma, which could be the ultimate partners in drug development and commercialisation.
Management: Management comprises Professor Andy Whiting, the company Chief Executive and a world leading chemist & scientist, supported by an experienced biology & pharmaceutical industry team.